Sofinnova Partners Closes $93.4M MD Start IV Fund

Sofinnova Partners has closed its MD Start IV fund at $93.4 million, with plans to launch six to eight start-ups from the vehicle, the firm announced.

The figure marks the latest closing in Sofinnova's MD Start program, a venture-building strategy that creates companies directly rather than backing existing ones. The fund's stated purpose is straightforward: seed and launch between six and eight new biotech ventures drawn from scientific and clinical innovation.

Sofinnova Partners, the Paris-headquartered life sciences investment firm, has operated the MD Start franchise across successive generations of funds. The strategy sits apart from conventional venture capital. Instead of writing checks into companies that already exist, the firm assembles them — identifying assets, recruiting founding teams, and capitalizing the new entities from day one through the MD Start vehicle.

The $93.4 million close gives the fourth iteration of the program fresh dry powder. Sofinnova plans to deploy it across a pipeline of six to eight new companies, according to the announcement. That per-company math implies an average initial allocation in the low-to-mid teens of millions of dollars per launch, consistent with the capital requirements of company creation in European biotech, where asset-centric builds typically start lean and syndicate follow-on capital as programs mature.

The venture-building model carries a distinct risk-return profile compared with traditional seed investing. Companies built inside a fund structure arrive with a pre-selected asset, an institutional anchor investor, and often a founding team recruited specifically for the scientific opportunity. That reduces formation risk — the classic failure point where promising science never finds a team or a first cheque. It also concentrates exposure: the fund's returns depend heavily on the quality of the assets chosen at the outset, before any market validation exists.

For Sofinnova, MD Start IV extends a franchise the firm has run across multiple funds and market cycles. The firm's portfolio strategy spans therapeutics, medical devices, and digital health, and the MD Start program functions as its earliest-stage entry point — earlier than angel rounds, earlier than most seed funds, at the moment when a company exists only as a plan.

The fund close also lands in a European biotech financing environment where early-stage capital has become more selective. Founding-round sizes have come under scrutiny as investors prioritize capital efficiency, and venture-building models have gained traction partly because they promise disciplined company construction from the first dollar. A dedicated pool of $93.4 million targeting six to eight launches signals institutional confidence in that approach despite the tougher climate.

What happens next is defined by the fund's own targets. Six to eight new companies will emerge from MD Start IV, each launched by Sofinnova Partners with capital from the closed vehicle. The first of those launches will offer the earliest read on how the firm deploys its fourth generation of venture-building capital — and on which scientific bets it has chosen to make.